Cargando…
Biologic Therapy in Refractory Non-Multiple Sclerosis Optic Neuritis Isolated or Associated to Immune-Mediated Inflammatory Diseases. A Multicenter Study
We aimed to assess the efficacy of biologic therapy in refractory non-Multiple Sclerosis (MS) Optic Neuritis (ON), a condition more infrequent, chronic and severe than MS ON. This was an open-label multicenter study of patients with non-MS ON refractory to systemic corticosteroids and at least one c...
Autores principales: | Herrero-Morant, Alba, Álvarez-Reguera, Carmen, Martín-Varillas, José L., Calvo-Río, Vanesa, Casado, Alfonso, Prieto-Peña, Diana, Atienza-Mateo, Belén, Maiz-Alonso, Olga, Blanco, Ana, Vicente, Esther, Rúa-Figueroa, Íñigo, Cáceres-Martin, Laura, García-Serrano, José L., Callejas-Rubio, José Luis, Ortego-Centeno, Norberto, Narváez, Javier, Romero-Yuste, Susana, Sánchez, Julio, Estrada, Paula, Demetrio-Pablo, Rosalía, Martínez-López, David, Castañeda, Santos, Hernández, José L., González-Gay, Miguel Á., Blanco, Ricardo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464396/ https://www.ncbi.nlm.nih.gov/pubmed/32796717 http://dx.doi.org/10.3390/jcm9082608 |
Ejemplares similares
-
Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis
por: Callejas-Rubio, José Luis, et al.
Publicado: (2008) -
Un mundo, una salud: la epidemia por el nuevo coronavirus COVID-19
por: Callejas Rubio, José Luis, et al.
Publicado: (2020) -
One world, one health: The novel coronavirus COVID-19 epidemic()
por: Callejas Rubio, José Luis, et al.
Publicado: (2020) -
Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review
por: Álvarez-Reguera, Carmen, et al.
Publicado: (2022) -
Off-Label Uses of Anti-TNF Therapy in Three Frequent Disorders: Behçet's Disease, Sarcoidosis, and Noninfectious Uveitis
por: Sánchez-Cano, Daniel, et al.
Publicado: (2013)